Mankind Pharma Limited has appointed Anish Vanraj Bafna as an Independent Director on its Board, bringing more than three decades of experience across healthcare, medical technology, international business and general management to the pharmaceutical company’s leadership.

Bafna’s appointment was approved by the Mankind Pharma Board with effect from August 10, 2026, initially as an Additional Director designated as a Non-Executive Independent Director. The appointment was proposed for a five-year term, subject to shareholder approval. Mankind Pharma subsequently received shareholder approval for the appointment through a postal ballot in September.

According to the company’s disclosure, Bafna brings more than 30 years of professional experience in the healthcare and medical devices sector, including extensive exposure to international markets and healthcare business management.

Bafna most recently served as Chief Executive Officer and Managing Director of Healthium Medtech Limited, a role he held for more than eight years. He currently serves as Non-Executive Chairman of Healthium Medtech. During his tenure, he was involved in the company’s growth, global expansion and organisational transformation.

Prior to Healthium, Bafna held senior leadership positions at Baxter International, including President – Japan and Regional Head – Emerging Asia. His responsibilities during his Baxter career included operations across India and Southeast Asian markets, giving him experience across multiple healthcare and business environments.

Bafna holds a Bachelor’s degree in Science (Chemistry) from St. Xavier’s, Ahmedabad, and a Post Graduate Diploma in Management from IMDR, Pune. Mankind Pharma’s disclosure also states that he meets the prescribed independence criteria under applicable corporate and securities regulations.

Mankind Pharma’s current Board profile lists Bafna among its Independent Directors. Commenting on his appointment on social media, Bafna described his association with Mankind Pharma as an opportunity to contribute to a company he has admired for its journey from a challenger brand to a major pharmaceutical and healthcare company. He also highlighted the company’s focus on healthcare accessibility, affordability, innovation and long-term value creation.

Also read: Google.org Invests $30 Million in AI for Government and Public Health Innovation

The appointment adds healthcare and medical-technology leadership experience to Mankind Pharma’s Board as the company continues to operate across pharmaceuticals, consumer healthcare and international markets.

Like

Dislike

Be a part of Elets Collaborative Initiatives. Join Us for Upcoming Events and explore business opportunities. Like us on Facebook , connect with us on LinkedIn and follow us on Twitter , Instagram.

"Exciting news! Elets technomedia is now on WhatsApp Channels Subscribe today by clicking the link and stay updated with the latest insights!" Click here!